Compare HRZN & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRZN | PRLD |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.5M | 260.2M |
| IPO Year | 2010 | 2020 |
| Metric | HRZN | PRLD |
|---|---|---|
| Price | $3.73 | $3.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $4.71 | ★ $9.20 |
| AVG Volume (30 Days) | ★ 507.8K | 287.6K |
| Earning Date | 11-05-2026 | 11-24-2026 |
| Dividend Yield | ★ 19.15% | N/A |
| EPS Growth | ★ 62.50 | 23.21 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | $0.10 | $220.54 |
| Revenue Next Year | $17.78 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $3.70 | $1.30 |
| 52 Week High | $6.78 | $6.83 |
| Indicator | HRZN | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 31.65 | 40.61 |
| Support Level | N/A | $3.38 |
| Resistance Level | $4.75 | $4.12 |
| Average True Range (ATR) | 0.17 | 0.34 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 12.44 | 19.39 |
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.